Why is Samrat Pharmachem Ltd falling/rising?

Recent Price Movement and Market Performance

Samrat Pharmachem’s shares have been under pressure, hitting a new 52-week low of Rs. 210 on the day. The stock opened sharply lower with a gap down of 5.2%, signalling immediate bearish sentiment among investors. Over the past week, the stock has declined by 7.7%, significantly underperforming the Sensex’s modest 1.83% fall. This negative momentum extends over longer periods as well, with the stock falling 16.61% in the last month compared to the Sensex’s 1.63% decline, and a year-to-date loss of 5.39% against the benchmark’s 1.58% drop.

More concerning is the stock’s long-term underperformance. Over the past year, Samrat Pharmachem has delivered a steep negative return of 39.64%, while the Sensex has gained 8.4%. Over three years, the stock’s cumulative loss exceeds 70%, in stark contrast to the Sensex’s nearly 40% gain. Even over five years, despite a positive return of 71.15%, the stock barely outpaces the Sensex’s 69.39%, indicating a lacklustre performance relative to the broader market.

Technical Indicators and Trading Activity

From a technical perspective, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests sustained downward pressure and a lack of near-term buying interest. The weighted average price indicates that most trading volume occurred near the day’s low, reinforcing bearish sentiment. Additionally, investor participation appears to be waning, with delivery volumes on 9 Jan falling by over 80% compared to the five-day average, signalling reduced conviction among shareholders.

Fundamental Weaknesses and Valuation Concerns

Underlying the share price decline are the company’s weak fundamentals. Samrat Pharmachem reported flat financial results in September 2025, with operating cash flows at a negative Rs. 10.09 crores and a quarterly PBDIT loss of Rs. 0.36 crores. The operating profit margin relative to net sales also hit a low of -0.46%, highlighting operational inefficiencies. Despite these challenges, the stock trades at a premium valuation with a price-to-book ratio of 0.9 and a return on equity of just 2.2%, which is expensive given the company’s deteriorating profitability.

Profitability has sharply declined, with net profits falling by 75.9% over the past year. This erosion of earnings power has contributed to the stock’s poor returns and consistent underperformance against the BSE500 benchmark over the last three years. Although foreign institutional investors have marginally increased their holdings to 3.24% this quarter, this has not translated into positive price momentum.

Conclusion: Why the Stock Is Falling

The decline in Samrat Pharmachem’s share price on 12-Jan is a reflection of its ongoing operational losses, weak cash flows, and deteriorating profitability. The stock’s consistent underperformance relative to the Sensex and sector peers over multiple time horizons underscores investor concerns about its long-term prospects. Technical indicators and reduced investor participation further compound the negative outlook. While foreign institutional investors have slightly increased their stake, this has not been sufficient to offset the broader negative sentiment driven by fundamental weaknesses and expensive valuation metrics. As a result, the stock continues to face downward pressure, making it a challenging proposition for investors seeking stable returns in the pharmaceutical sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →